Mobocertinib/Mobocertinib (Mobocertinib) effects and efficacy

Mobocertinib/Mobocertinib(Mobocertinib) is an oral kinase inhibitor that was previously Approved for the treatment of adults with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations that have progressed during or after platinum-based chemotherapy. This is a first-in-class oral therapy designed specifically to target the EGFRexon 20 insertion mutation.

Mobocertinib/Mobocertinib(Mobocertinib)The recommended dose is 160 mg once daily, with or without food, until disease progression or unacceptable toxicity. . Based on research in an international, non-randomized, open-label, multiple short-term clinical trial (NCT02716116), including patients with locally advanced or metastatic non-small cell lung cancer with an EGFR exon 20 insertion mutation. Efficacy was evaluated in 114 patients whose disease progressed during or after platinum-based chemotherapy. Patients received oral 160 mgmobotinib daily until disease progression or unacceptable toxicity occurred. The primary efficacy outcome measures were overall response rate(ORR) and duration of response assessed by blinded independent central review(BICR) according to RECIST 1.1. ORR is 28% (95% confidence interval: 20%, 37%), with a median duration of response of 17.5 /span>months(95%confidence interval:7.4, 20.3). If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.